Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acrivon Therapeutics, Inc.

1.35
+0.10008.00%
Post-market: 1.34-0.0099-0.73%19:59 EDT
Volume:688.59K
Turnover:914.65K
Market Cap:42.33M
PE:-0.61
High:1.37
Open:1.26
Low:1.24
Close:1.25
Loading ...

Acrivon Therapeutics, Inc. (ACRV) was downgraded to a Hold Rating at JonesTrading

TIPRANKS
·
17 May

Acrivon Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
16 May

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating

MT Newswires Live
·
15 May

Acrivon Therapeutics Inc. : Oppenheimer Cuts Target Price to $9 From $10

THOMSON REUTERS
·
15 May

Acrivon Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

BRIEF-Acrivon Therapeutics, Inc Q1 Income From Operations USD -21.662 Million

Reuters
·
15 May

Acrivon Therapeutics, Inc Q1 Operating Expenses USD 21.662 Million

THOMSON REUTERS
·
15 May

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now

Zacks
·
05 May

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

GlobeNewswire
·
25 Apr

April 2025's Standout Penny Stocks

Simply Wall St.
·
23 Apr

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

Zacks
·
14 Apr

Acrivon Therapeutics Names Dr. Mirza as Medical Chief

Dow Jones
·
08 Apr

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief

MT Newswires Live
·
08 Apr

Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer

TIPRANKS
·
08 Apr

Press Release: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Dow Jones
·
08 Apr

BUZZ-Maxim cuts Acrivon PT on deprioritization of ovarian and bladder programs

Reuters
·
01 Apr

Acrivon Therapeutics Inc : Maxim Group Cuts Target Price to $7 From $24

THOMSON REUTERS
·
01 Apr

Acrivon Therapeutics Inc : Jefferies Cuts Target Price to $14 From $18

THOMSON REUTERS
·
31 Mar

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Zacks
·
29 Mar

Acrivon Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar